

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **DTXS Silk Road Investment Holdings Company Limited**

**大唐西市絲路投資控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 620)**

### **CHANGE OF DIRECTORS AND CHANGE IN COMPOSITION OF BOARD COMMITTEE**

The Board announces the following change of directors and change in composition of board committee with effect from 1 April 2022:

1. Dr. Xu Zhihong has been appointed as an Executive Director, Executive Vice-chairman, the Chairman of the Investment Committee and a member of the Remuneration Committee of the Company;
2. Dr. Ma Chao has resigned as an Executive Director and Executive Vice-chairman, also ceased to be the Chairman of the Investment Committee and a member of the Remuneration Committee of the Company.

The board of directors (the “**Board**”) of DTXS Silk Road Investment Holdings Company Limited (the “**Company**”) announces the following change of directors and change in composition of board committee with effect from 1 April 2022:

#### **Appointment of Executive Director and Executive Vice-chairman**

Dr. Xu Zhihong (“**Dr. Xu**”), was appointed as an Executive Director, an Executive Vice-chairman, the Chairman of the Investment Committee and a member of the Remuneration Committee of the Company on 1 April 2022. Dr. Xu will focus on the development of operations of the Company and its subsidiaries (the “**Group**”).

Dr. Xu, aged 59, had been appointed as a Co-Chief Executive Officer of the Company on 16 June 2020. He had been appointed as an Executive Director and a member of the Investment Committee of the Company, also had been re-designated as the Chief Executive Officer of the Company on 1 September 2020. He further was re-designated as a Co-Chief Executive Officer of the Company on 12 March 2021. He subsequently resigned as an Executive Director and a Co-Chief Executive Officer of the Company, also ceased to be a member of the Investment Committee of the Company on 1 September 2021.

Dr. Xu graduated from Anhui Finance and Trade Vocational College with a Bachelor of Economics degree, and then obtained a Master of Business Administration degree from Oklahoma City University and a Doctorate degree in Economics from Renmin University of China. He was the managing director of Wing Lung Bank Limited and general manager of the Financial Markets Department of Industrial and Commercial Bank of China, and has extensive experience in corporate financial planning. Dr. Xu was a director and deputy general manager of China Dive Company Limited (stock code: 300526), a company listed on the Shenzhen Stock Exchange, from 2 December 2019 to 3 June 2020. Dr. Xu has received the honour of Special Government Allowances of the State Council as a National Expert (國務院特殊津貼專家), and he has also served as a committee member of the Financial Products Committee of the People's Bank of China and a council member of the China Urban Financial Society.

Pursuant to the appointment agreements between Dr. Xu and the Company, the term of his appointment as Executive Director is for an initial term of one year and there is no specified term for his appointment as Executive Vice-chairman. The appointment agreements can be terminated by either party giving one month's written notice. Dr. Xu's appointment of Executive Director is subject to retirement by rotation and re-election in accordance with the bye-laws of the Company and the Listing Rules. Pursuant to the terms of appointment, Dr. Xu is entitled to an aggregate annual remuneration of HK\$3,000,000. Dr. Xu's remuneration is recommended by the Remuneration Committee of the Company and determined by the Board with reference to his duties and responsibilities with the Company and prevailing market conditions.

As at the date of this announcement, save as disclosed above, Dr. Xu (i) does not have any interest in the shares of the Company within the meaning of Part XV of the SFO; (ii) does not have any relationship with any director, senior management, substantial or controlling shareholder of the Company; (iii) does not hold any other positions with the Company and/or its subsidiaries; and (iv) does not hold any directorship in the last three years immediately preceding the date of this announcement in public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

Save as disclosed above, there is no other matter relating to the appointment of Dr. Xu that needs to be brought to the attention of the shareholders of the Company and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to extend its welcome to Dr. Xu on their new appointment.

### **Resignation of Executive Director and Executive Vice-chairman**

Dr. Ma Chao (“**Dr. Ma**”) has resigned as an Executive Director and an Executive Vice-chairman of the Company, also ceased to be the Chairman of the Investment Committee and a member of the Remuneration Committee of the Company due to his other business commitments with effect from 1 April 2022.

Dr. Ma confirmed that he has no disagreement with the Board and there is no other matter in relation to his resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited.

The Board would like to take this opportunity to express its gratitude to Dr. Ma for his valuable contributions to the Company during their term of office.

By Order of the Board  
**DTXS Silk Road Investment Holdings Company Limited**  
**Lu Jianzhong**  
*Executive Director and Chairman*

Hong Kong, 1 April 2022

*As at the date of this announcement, the Board comprises five Executive Directors, namely Mr. Lu Jianzhong (Chairman), Mr. Yang Xingwen, Mr. Xu Zhihong (Executive Vice-chairman), Mr. Kam Hou Yin John (Chief Executive Officer) and Mr. Wong Kwok Tung Gordon Allan (Deputy Chief Executive Officer); and three Independent Non-executive Directors, namely and Mr. Tsang Yok Sing, Jasper, Mr. Tse Yung Hoi and Mr. Kwok Chi Shing.*